Allscripts Healthcare Solutions (NASDAQ:MDRX) has been assigned a $19.00 price target by equities researchers at Wells Fargo & Co in a research report issued to clients and investors on Saturday, February 17th. The firm presently has a “buy” rating on the software maker’s stock. Wells Fargo & Co’s target price suggests a potential upside of 39.50% from the stock’s previous close.
A number of other analysts have also commented on MDRX. Zacks Investment Research upgraded Allscripts Healthcare Solutions from a “sell” rating to a “hold” rating in a report on Thursday, January 25th. Citigroup started coverage on Allscripts Healthcare Solutions in a report on Thursday, January 4th. They issued a “buy” rating on the stock. Cantor Fitzgerald restated a “buy” rating and issued a $17.00 price target on shares of Allscripts Healthcare Solutions in a report on Sunday, January 28th. TheStreet upgraded Allscripts Healthcare Solutions from a “c” rating to a “b-” rating in a report on Thursday, February 15th. Finally, KeyCorp restated a “hold” rating on shares of Allscripts Healthcare Solutions in a report on Friday, October 27th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and twelve have assigned a buy rating to the company. Allscripts Healthcare Solutions currently has an average rating of “Buy” and an average target price of $16.09.
Allscripts Healthcare Solutions (MDRX) traded down $0.12 during trading hours on Friday, reaching $13.62. The company’s stock had a trading volume of 1,531,078 shares, compared to its average volume of 2,065,224. Allscripts Healthcare Solutions has a 1 year low of $11.25 and a 1 year high of $16.13. The company has a current ratio of 0.97, a quick ratio of 0.97 and a debt-to-equity ratio of 1.33. The firm has a market capitalization of $2,460.00, a PE ratio of -10.40, a price-to-earnings-growth ratio of 1.82 and a beta of 1.19.
Allscripts Healthcare Solutions (NASDAQ:MDRX) last posted its earnings results on Thursday, February 15th. The software maker reported $0.18 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.18. Allscripts Healthcare Solutions had a positive return on equity of 7.36% and a negative net margin of 10.88%. The firm had revenue of $547.00 million during the quarter, compared to analysts’ expectations of $524.05 million. During the same period in the previous year, the firm earned $0.14 earnings per share. The company’s revenue was up 27.5% on a year-over-year basis. equities analysts expect that Allscripts Healthcare Solutions will post 0.56 earnings per share for the current year.
In related news, EVP Brian Farley sold 5,000 shares of the company’s stock in a transaction dated Thursday, December 14th. The stock was sold at an average price of $14.35, for a total transaction of $71,750.00. Following the sale, the executive vice president now owns 191,607 shares in the company, valued at $2,749,560.45. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, President Richard J. Poulton sold 15,000 shares of the company’s stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $14.26, for a total value of $213,900.00. Following the sale, the president now owns 1,351,773 shares in the company, valued at approximately $19,276,282.98. The disclosure for this sale can be found here. Corporate insiders own 0.91% of the company’s stock.
Large investors have recently added to or reduced their stakes in the business. Zeke Capital Advisors LLC bought a new stake in Allscripts Healthcare Solutions in the fourth quarter valued at approximately $165,000. Sheaff Brock Investment Advisors LLC bought a new stake in Allscripts Healthcare Solutions in the third quarter valued at approximately $174,000. Quantitative Systematic Strategies LLC bought a new stake in Allscripts Healthcare Solutions in the fourth quarter valued at approximately $182,000. Avestar Capital LLC bought a new stake in Allscripts Healthcare Solutions in the fourth quarter valued at approximately $173,000. Finally, Crossmark Global Holdings Inc. bought a new stake in Allscripts Healthcare Solutions in the third quarter valued at approximately $187,000.
ILLEGAL ACTIVITY WARNING: This article was reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this article on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright law. The correct version of this article can be read at https://ledgergazette.com/2018/03/14/wells-fargo-co-analysts-give-allscripts-healthcare-solutions-mdrx-a-19-00-price-target.html.
About Allscripts Healthcare Solutions
Allscripts Healthcare Solutions, Inc (Allscripts) delivers information technology (IT) solutions and services to help healthcare organizations. The Company operates through three segments: Clinical and Financial Solutions, Population Health, and Netsmart. The Clinical and Financial Solutions segment includes the sale of integrated clinical software applications and financial and information solutions.
Receive News & Ratings for Allscripts Healthcare Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allscripts Healthcare Solutions and related companies with MarketBeat.com's FREE daily email newsletter.